Jacqueline Rhuda

Jacqueline Rhuda is an Analyst in Quantitative Research and Strategy at RA Capital Management, a leading healthcare investment firm in Boston, Massachusetts. In her role, she applies advanced quantitative and data-driven methodologies to help inform strategic investment decisions, with a focus on healthcare and life sciences companies developing therapeutics, medical devices, and diagnostics. Her analytical contributions support RA Capital’s investments across both public and private markets within the biotech and healthcare innovation sectors.

Prior to her current position, Jacqueline advanced through several roles at RA Capital, previously serving as Senior Associate and Associate in the same division from early 2023 through April 2025. Her work has included major projects such as applying artificial intelligence algorithms to analyze performance patterns within core and peripheral biotech equity holdings, which informed the design of novel ETF portfolios targeting development-stage biotechnology stocks.

Jacqueline holds a Bachelor of Science in Molecular and Cellular Biology from The Johns Hopkins University, providing her with deep subject-matter expertise in the scientific and technical aspects of healthcare investing. Her career highlights include presentations on healthcare policy and reimbursement trends, notably at industry conferences such as ISPOR Europe 2024, and recognized contributions to pioneering quantitative research that shapes investment strategies in the biotech sector.